Portfolio | 鹍远基因完成6000万美元A+轮融资

2018年3月28日，鹍远基因宣布成功完成6000万美金的A+轮融资。本轮融资由松禾资本和景旭创投领投，先锋医疗投资、九州通医药集团、礼来亚洲基金等新老投资者跟投。

鹍远基因在中国上海和美国加州圣地亚哥设有研发和营运中心。公司专注于开发早期癌症的无创基因检测，致力于通过癌症的早期发现和精准诊断，努力为病人提供早期、精准、全面的诊疗信息，改善癌症患者的临床疗效。鹍远已经开发了一系列基于游离DNA（cfDNA）分析的独有专利技术，主要产品和服务涵盖肿瘤筛查、诊断及个体化治疗等，尤其在利用高通量甲基化测序技术进行循环肿瘤DNA（ctDNA）检测和癌症早期诊断方面取得了卓越的进展。

本轮融资将有助于鹍远基因扩大其无创基因检测的硏发及商业化，加速其早期癌症筛查和诊断产品的临床验证和上市。鹍远基因计划进一步扩大公司研究设施，利用TiTanSeq™和MONOD™等技术研发新的产品线，加快解决癌症的早期检测、诊断及个性化治疗。

鹍远基因董事长高远教授表示: "我们感谢现有投资者的持续支持, 也欢迎新投资者加入鹍远大家庭。鹍远的专利技术, 如 TiTanSeq™和 MONOD™可以大大提高早期癌症检测的准确性, 并显著提高患者的生存机会。这次成功融资使我们得到充分的资源，继续加速推进我们的创新研究和研发项目，使鹍远基因稳居癌症早期检测开发的国际领导地位。

“我们非常高兴继续与鹍远基因合作，帮助公司继续在早期癌症检测领域持续发展，” 松禾资本管理合伙人罗飞表示，“鹍远正在改变癌症检测的模式，可能带来肿瘤诊疗领域的突破性进展。”

景旭创投管理合伙人钱庭栀表示：“鹍远管理团队、专利技术以及他们对癌症早期检测研发的承诺给我们留下了非常深刻印象，通过这次融资，我们相信鹍远将加速其研发和业务发展进程。”

上海鹍远生物技术有限公司  

www.singlera.com.cn

上海鹍远生物技术有限公司（鹍远基因）于2014年7月在加利福尼亚州圣地亚哥由高远教授（约翰霍普金斯大学），张鹍教授（加州大学圣地亚哥分校）联合其他创始人张江立（CEO）、刘强（COO）、刘蕊博士（CTO）共同创建。公司目前在圣地亚哥和上海都拥有研发中心和商务运营中心。鹍远基因在单细胞测序、DNA 甲基化测序和生物信息学方面拥有多项专利技术。

鹍远基因致力于将新一代基因测序技术应用于遗传和肿瘤等疾病的诊断。公司专注研发无创基因检测技术，包括单细胞测序、DNA甲基化测序和机器学习等，以满足早期癌症的检测，肿瘤个性化治疗、产前诊断和胚胎植入前筛查等健康需求；此外也为制药企业和医疗研究机构提供定制化的测序研究服务。

松禾资本 

www.pinevc.com.cn

松禾资本管理有限公司是由深港产学研创业投资有限公司于2007年发起设立的专业化创业投资管理公司。松禾资本团队拥有18年以上创业投资经验，具备丰富的行业背景和资本运作经验。松禾资本目前受托管理资产超过90亿元人民币, 投资超过50亿元人民币，累计投资企业200多家，已有36家企业IPO或被上市公司并购。医疗健康是松禾资本重点关注的领域之一，其曾经投资过华大基因、七桥基因、碳云基因、第一健康、北科生物、一心药业、合一康生物、博德嘉联医生集团等知名企业。

景旭创投  

www.prosperico-venture.com

景旭创投是优质的人民币创投基金管理基金，以上海为发展基地，专注于医疗健康和相关高科技行业风险投资和并购的专业机构。景旭创投拥有实业家的愿景，是优秀创业者和企业家成长发展的长期伙伴。景旭创投已支持超过30家企业, 在中国和境外发展, 跨越药物研发, 诊断, 创新医疗设备和医疗保健服务。企业的主要投资组合包括上海博威生物医药有限公司、上海科志康医药科技有限公司、莱诺医疗技术（上海）有限公司、BioNano Genomics, Inc、深圳市友睦口腔股份有限公司、中国脐带血库企业集团等知名企业

礼来亚洲基金

www.lillyasiaventures.com

礼来亚洲基金（Lilly Asia Ventures）成立于2008年，总部设在上海，公司致力于生命科学和医疗保健领域为重点的风险投资，主要专注于亚洲尤其是中国生物医药、生物技术、医疗器械、医疗服务和动物保健领域的股权投资。作为领先的生物医药风险基金，礼来亚洲基金对于标的企业提供“智慧资本”以及全球化资源，加速企业成长。

上海鹍远生物技术有限公司

媒体联系方式:

Julia Zhu(86) 80113170-1012

Email Contact:

[e-mail]

投资者联系方式：

Yvonne Jia (86) 13564304046

Email Contact:

[e-mail]

附英文新闻：

Singlera Genomics Raises $60 Million in Series A+ Financing

LA JOLLA, Calif., March 27, 2018/PRNewswire/ -- Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, today announced that it has successfully secured a US$60 million Series A+ financing round led by Green Pine Capital Partners and Prosperico Ventures with participation from new and existing investors, UCF Medical Investment, Jointown Pharmaceutical Group, and Lilly Asia Ventures among others.

Based in La Jolla and Shanghai, Singlera has developed proprietary technologies related to the analysis of cell-free DNA. Singlera's main products and services include cancer screening, diagnosis and personalized treatment. Singlera is striving to improve clinical outcomes for cancer patients through early-stage detection and accurate and informative cancer diagnoses. Singlera has made remarkable progress on applying high-throughput sequencing of methylated circulating tumor DNA (ctDNA) to detecting and diagnosing early-stage cancer.

The funds will help Singlera expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies. Singlera will also use the funds tofurther expand its research facilities and its TiTanSeq™ and MONOD™ platforms into new product lines that address early cancer detection, diagnosis and personalized treatment.

Dr. Yuan Gao, Chairman of Singlera Genomics, said "We are grateful for the continued support of our existing investors, and we welcome the new investors to the Singlera family. Singlera's proprietary technologies such as TiTanSeq™ and MONOD™ could substantially enhance the accuracy of cancer detection at early stages and significantly improve patients' survival chances. This new funding will give us significant runway to continue to advance our innovative research and development programs, and we are poised to become the world leader in early-stage cancer detection."

"We are excited to continue to support Singlera Genomics to help the company continue to strive in the field of early-stage cancer detection," said Mr. Luo Fei, Managing partner, Green Pine Venture Partners. "Singlera is working to change the paradigm of cancer detection and may lead to important advances in oncology."

"We've been very impressed with the strength of their management team, proprietary technologies and their commitment to cancer early detection," said Mr. Qian Tingzhi, Managing Partner, Prosperico Venture Partners. "With this financing, we believe that the company will accelerate in its pipeline and business development opportunities."

Singlera Genomics Inc. (www.singlera.com)

Singlera Genomics Inc., a company focusing on non-invasive genetic diagnosis, was co-founded in July 2014 in San Diego, California by Yuan Gao, PhD, Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang(CEO), Mr. Qiang Liu (COO), and Dr. Rui Liu(CTO). The company currently has R&D centers and business operations in both La Jolla, California, and Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics.

Singlera Genomics is committed to the application of next generation sequencing to diagnose genetic diseases and disorders. Singlera Genomics develops non-invasive genetic tests using proprietary technologies including single cell sequencing, DNA methylation sequencing and machine learning. Singlera Genomics' products address the continuing needs for early-stage cancer detection, personalized cancer treatment, prenatal diagnosis, and pre-implantation genetic screening. Additionally, Singlera Genomics provides customized next generation sequencing services to pharmaceutical companies and medical research institutions. It has operation centers in the United States and China.

Green Pine Capital Partners (www.pinevc.com.cn)

Green Pine Capital Partners (GPCP) was established in 2007 in Shengzhen, China. With the vision of "Becoming one of the most valuable investment institutions", Green Pine Capital is playing active roles in funding & nurturing early to high growth-stage innovative enterprises. Green Pine Capital is ranked among the highest performing VC/PE firms in China, our core investment team have over 20 years of experience on venture capital investments.

Prosperico Ventures (www.prosperico-venture.com)

A Shanghai-based venture capital fund specialized in healthcare investments, Prosperico Venture has backed more than 30 companies growing their business both in and outside of China across drug discovery & development, diagnostics, innovative medical devices and healthcare service. Major portfolios of Prosperico Venture include Mab-Ventures, Pharmalegacy, BioNano, BioMedomics, U-Dental, China Cord Blood Corporation, etc. 

Lilly Asia Ventures (www.lillyasiaventures.com)

Lilly Asia Ventures, founded in 2008 and headquartered in Shanghai, is a life sciences and healthcare sector focused venture capital firm, focusing predominantly on biopharmaceutical, med tech and diagnostics investments in Asia, particularly in China. As a leading biomedical venture fund, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.

SOURCE Singlera Genomics

Related Links

http://www.singlera.com

近期文章：

欢迎关注：